{"success":true,"data":{"pressRelease":{"id":"76352","rtpr_id":"nGNE1gds3w","ticker":"HBC","exchange":"Oslo Børs","all_tickers":["HBC"],"title":"REG-HOFSETH BIOCARE ASA: ANNUAL GENERAL MEETING COMPLETED","author":"Globe Newswire","published_at":"2026-06-30T10:50:10.060Z","article_body":"Hofseth BioCare ASA held its Annual General Meeting on 30 June 2026.\nAll proposals were resolved as presented in the notice issued on 9 June 2026.\n\nThe minutes from the Annual General Meeting are attached.\n\nFor further information, please contact:\nJon Olav Ødegård, CEO at HBC\nPhone: +47 936 32 966\nE-mail: joo@hofsethbiocare.no\n\nAbout Hofseth BioCare ASA:\nHBC is a Norwegian consumer and pet health company founded on the core values\nof sustainability, optimal utilization of natural resources and full\ntraceability. It upcycles the side streams of the salmon industry by taking\nfresh filleted salmon and converting it from a waste product into ingredients\nto improve human and pet health.\n\nThese ingredients are ProGo®, a mix of bioactive peptides and collagen,\nOmeGo®, a whole salmon oil, with all the fatty acid fractions contained in\nfish, and CalGo® / NT-II® salmon bone powder containing calcium\nhydroxyapatite and undenatured collagen for bone and joint health.\n\nHBC places scientific evidence at the forefront which has led to important\nacademic partnerships and the identification of unique health benefits. This\nincludes the demonstration of improved iron metabolism by boosting the body's\nability to take up and use iron resulting in increased energy and vitality\nwith ProGo® as well as the activation of the GLP-1 receptor with fat\nreduction in overweight adults. OmeGo® has shown important immune health\nbenefits including recovery from viral infection and improved respiratory\nhealth and sleep in adults troubled by particulate matter pollution. Finally,\nCalGo® has shown both bone and joint health benefits to support healthy\nageing and active lifestyles. This work has also resulted in the granting of a\nnumber of patents protecting these discoveries. It has also led to the\ndiscovery of potential therapeutics and HBC has spun out a biotech-focused\ncompany, AecorBio Inc. (formerly HBC Immunology) which has raised external\nfinance, and the lead program is in prostate cancer followed by ovarian\ncancer. A separate molecule is targeted as an oral, steroid-sparing therapy\nfor asthma. HBC's headquarters are in Ålesund, Norway with branches in Oslo,\nLondon, Zürich and Palo Alto.\n\nHBC is listed on Oslo Børs with ticker \"HBC\".\n\nAttachment\n*     Minutes Annual General Meeting 2026\n(https://ml-eu.globenewswire.com/Resource/Download/53cfa299-7466-4661-80b5-6ec589bd5630)","article_body_html":"","raw_payload":{"data":{"id":"nGNE1gds3w","title":"REG-HOFSETH BIOCARE ASA: ANNUAL GENERAL MEETING COMPLETED","author":"Globe Newswire","ticker":"HBC","created":"2026-06-30T10:50:10.060Z","tickers":["HBC"],"exchange":"Oslo Børs","article_body":"Hofseth BioCare ASA held its Annual General Meeting on 30 June 2026.\nAll proposals were resolved as presented in the notice issued on 9 June 2026.\n\nThe minutes from the Annual General Meeting are attached.\n\nFor further information, please contact:\nJon Olav Ødegård, CEO at HBC\nPhone: +47 936 32 966\nE-mail: joo@hofsethbiocare.no\n\nAbout Hofseth BioCare ASA:\nHBC is a Norwegian consumer and pet health company founded on the core values\nof sustainability, optimal utilization of natural resources and full\ntraceability. It upcycles the side streams of the salmon industry by taking\nfresh filleted salmon and converting it from a waste product into ingredients\nto improve human and pet health.\n\nThese ingredients are ProGo®, a mix of bioactive peptides and collagen,\nOmeGo®, a whole salmon oil, with all the fatty acid fractions contained in\nfish, and CalGo® / NT-II® salmon bone powder containing calcium\nhydroxyapatite and undenatured collagen for bone and joint health.\n\nHBC places scientific evidence at the forefront which has led to important\nacademic partnerships and the identification of unique health benefits. This\nincludes the demonstration of improved iron metabolism by boosting the body's\nability to take up and use iron resulting in increased energy and vitality\nwith ProGo® as well as the activation of the GLP-1 receptor with fat\nreduction in overweight adults. OmeGo® has shown important immune health\nbenefits including recovery from viral infection and improved respiratory\nhealth and sleep in adults troubled by particulate matter pollution. Finally,\nCalGo® has shown both bone and joint health benefits to support healthy\nageing and active lifestyles. This work has also resulted in the granting of a\nnumber of patents protecting these discoveries. It has also led to the\ndiscovery of potential therapeutics and HBC has spun out a biotech-focused\ncompany, AecorBio Inc. (formerly HBC Immunology) which has raised external\nfinance, and the lead program is in prostate cancer followed by ovarian\ncancer. A separate molecule is targeted as an oral, steroid-sparing therapy\nfor asthma. HBC's headquarters are in Ålesund, Norway with branches in Oslo,\nLondon, Zürich and Palo Alto.\n\nHBC is listed on Oslo Børs with ticker \"HBC\".\n\nAttachment\n*     Minutes Annual General Meeting 2026\n(https://ml-eu.globenewswire.com/Resource/Download/53cfa299-7466-4661-80b5-6ec589bd5630)"},"type":"article","timestamp":"2026-06-30T10:50:10.140703568Z","server_sent_at_ms":1782816610140},"received_at":"2026-06-30T10:50:10.191Z","source_url":null},"analysis":{"id":"65629","press_release_id":"76352","analysis_json":{"industry":{"label":"Household & Personal Products","sector":"Consumer Staples"},"redFlags":[],"eventType":"other","narrative":"Hofseth BioCare ASA completed its Annual General Meeting on June 30, 2026, resolving all proposals as originally presented in the notice issued earlier in the month.\n\nThe company focuses on upcycling salmon industry side streams into bioactive ingredients like ProGo and OmeGo for the consumer and pet health markets.\n\nHBC also highlighted its scientific partnerships and the spin-out of biotech subsidiary AecorBio Inc., which is developing therapeutics for prostate and ovarian cancer.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine AGM completion; no new material information."},"keyFigures":null,"quotedText":"","namedEntities":{"people":[{"name":"Jon Olav Ødegård","role":"CEO"}],"products":["ProGo","OmeGo","CalGo","NT-II"],"companies":[{"name":"Hofseth BioCare ASA","ticker":"HBC"},{"name":"AecorBio Inc.","relationship":"spinout"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine corporate governance announcement confirming the Annual General Meeting was held and all proposals passed as presented. No material financial or strategic changes were disclosed."},"tickerRelevance":{"others":[],"primary":"HBC"},"globalImportance":5,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small_cap","eventGravity":"routine_administrative","sectorWeight":"niche_consumer_health"}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Hofseth BioCare ASA completed its Annual General Meeting on June 30, 2026, resolving all proposals as originally presented in the notice issued earlier in the month.\n\nThe company focuses on upcycling salmon industry side streams into bioactive ingredients like ProGo and OmeGo for the consumer and pet health markets.\n\nHBC also highlighted its scientific partnerships and the spin-out of biotech subsidiary AecorBio Inc., which is developing therapeutics for prostate and ovarian cancer.","key_figures":null,"named_entities":{"people":[{"name":"Jon Olav Ødegård","role":"CEO"}],"products":["ProGo","OmeGo","CalGo","NT-II"],"companies":[{"name":"Hofseth BioCare ASA","ticker":"HBC"},{"name":"AecorBio Inc.","relationship":"spinout"}],"dollarAmounts":[]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-06-30T10:52:58.706Z","global_importance":5,"audience_relevance":10,"importance_components":{"tickerTier":"small_cap","eventGravity":"routine_administrative","sectorWeight":"niche_consumer_health"}},"durationMs":115606,"modelName":"george-droid-qwen-72b"}}